Global Immunology Drugs Market In-depth forecast analysis by type Jarrett Stidham Hat , end-use, region by NiravGokani · January 30, 2019
ResearchMoz include new market research report “Global Immunology Drugs Market to 2022 – Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth” to its huge collection of research reports.
Immunology is a therapy area characterized by disorders of the immune system Hjalte Froholdt Hat , specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.
A number of therapies have been approved for immunological disorders Yodny Cajuste Hat , including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.
For more information on this report Damien Harris Hat , fill the form @ ;repid=1160848
Inflectra, a biosimilar of Remicade was recently approved by the FDA in 2016. However, the gradual uptake of biosimilars such as Inflectra is not expected to act as a strong growth driver for the biosimilar segment within the forecast period. This therefore means existing products such as Remicade are expected to maintain high revenues during the forecast period
Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2 Chase Winovich Hat ,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.
The report focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis
Thema drucken
14.05.2019 11:06
Antworten